Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Arqule Inc (ARQL)

Arqule Inc (ARQL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Replimune Appoints Dieter Weinand as Chairman and Paolo Pucci to the Board of Directors

Replimune Group Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic(TM) platform, today announced the appointment of Dieter Weinand as Chairman...

ARQL : 20.00 (+0.15%)
MRK : 76.55 (+3.73%)
REPL : 9.85 (+0.72%)
Merck Completes Acquisition of ArQule

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common...

MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
Moore Kuehn, PLLC Encourages Investors of KEM, ARQL, THOR, and LOGM to Contact the Firm

Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders:

KEM : 24.40 (+1.79%)
ARQL : 20.00 (+0.15%)
MRK : 76.55 (+3.73%)
THOR : 67.99 (unch)
LOGM : 83.00 (+0.12%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - INST, THOR, TCBI, ARQL

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

INST : 49.00 (+0.43%)
THOR : 67.99 (unch)
TCBI : 21.76 (+6.41%)
ARQL : 20.00 (+0.15%)
THOR, ARQL, TIF, and AMTD SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts

Rigrodsky & Long, P.A. announces that it is investigating:

ARQL : 20.00 (+0.15%)
AMTD : 34.92 (+2.68%)
THOR : 67.99 (unch)
TIF : 129.49 (+0.12%)
Merck Begins Tender Offer to Acquire ArQule

Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of ArQule, Inc. (Nasdaq:...

MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates Whether The Sale Of These Companies Is Fair To Shareholders - ARQL, KEM, CBPX, TECD

Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies:

ARQL : 20.00 (+0.15%)
KEM : 24.40 (+1.79%)
CBPX : 36.99 (unch)
TECD : 129.33 (+0.91%)
SHAREHOLDER ALERT: WeissLaw LLP Investigates ArQule, Inc.

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of ArQule, Inc. ("ArQule" or the "Company") (NASDAQ: ARQL) in connection with the...

ARQL : 20.00 (+0.15%)
MRK : 76.55 (+3.73%)
Why Biotech ETFs are Surging to New Highs

increasing M&A deals and cutting edge therapies are driving biotech ETFs higher

MRK : 76.55 (+3.73%)
SNY : 43.24 (+0.77%)
NVS : 83.11 (+2.69%)
IBB : 106.44 (+2.55%)
BBC : 27.21 (-0.27%)
SBIO : 29.81 (+0.71%)
XBI : 74.99 (+2.36%)
THOR : 67.99 (unch)
MDCO : 84.90 (-0.07%)
ARQL : 20.00 (+0.15%)
AUPH : 14.24 (+0.85%)
ARKG : 29.63 (+1.72%)
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of ArQule, Inc - ARQL

Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating ArQule, Inc ("ArQule"...

MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

AGN : 176.85 (+1.11%)
SNY : 43.24 (+0.77%)
ABBV : 74.74 (+1.80%)
MRK : 76.55 (+3.73%)
BMY : 55.08 (+0.47%)
IBB : 106.44 (+2.55%)
CNCR : 19.26 (+2.09%)
BBC : 27.21 (-0.27%)
XBI : 74.99 (+2.36%)
SBIO : 29.81 (+0.71%)
THOR : 67.99 (unch)
AMGN : 208.56 (+5.43%)
CELG : 108.24 (+0.10%)
ARQL : 20.00 (+0.15%)
G : 26.72 (-0.22%)
Merck to Buy ArQule for $2.7B to Boost Cancer Portfolio

Merck (MRK) offers to acquire ArQule for a deal value of $2.7 billion. The transaction will add ArQule's lead investigational candidate ARQ 531 to Merck's oncology portfolio.

SNY : 43.24 (+0.77%)
BMY : 55.08 (+0.47%)
MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
Company News for Dec 10, 2019

Companies in the news are: ARQL, THOR, CGC, FATE

THOR : 67.99 (unch)
FATE : 21.02 (+4.01%)
ARQL : 20.00 (+0.15%)
CGC : 13.78 (+1.47%)
Small Molecule Oncology Drug Market Forecast to Exceed $66 Billion in 2019

Much R&D from companies and investors has been pouring into the targeted drug therapies markets, enabling pharma companies and other industry researchers to find better and more effective ways to combat...

CNSP : 2.08 (+1.30%)
CLVS : 5.82 (+2.28%)
ARQL : 20.00 (+0.15%)
APTO : 5.66 (-4.71%)
APS.TO : 8.16 (-3.43%)
FATE : 21.02 (+4.01%)
ArQule Reaches Analyst Target Price

In recent trading, shares of ArQule Inc. have crossed above the average analyst 12-month target price of $13.57, changing hands for $19.70/share.

ARQL : 20.00 (+0.15%)
Pharma M&As Continue, Merck, Sanofi to Buy Cancer Drug Firms

Merck offers to buy ArQule for $2.7 billion while Sanofi signs a definitive deal to purchase Synthorx for $2.5 billion.

SNY : 43.24 (+0.77%)
MRK : 76.55 (+3.73%)
THOR : 67.99 (unch)
ARQL : 20.00 (+0.15%)
ARQULE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of ARQL and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized stockholder law firm, has launched an investigation into whether the board members of ArQule, Inc. (NASDAQ: ARQL) breached their fiduciary duties or...

MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
ArQule Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of ArQule, Inc. is Fair to Shareholders; Investors Are Encouraged to Contact the Firm - ARQL

Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of ArQule, Inc. (NASDAQ: ARQL) to Merck for $20.00 per share is fair to ArQule shareholders. On behalf of ArQule shareholders,...

MRK : 76.55 (+3.73%)
ARQL : 20.00 (+0.15%)
Week Begins with Biotech Mergers

Week Begins with Biotech Mergers

SNY : 43.24 (+0.77%)
MRK : 76.55 (+3.73%)
RHHBY : 41.4700 (+1.64%)
THOR : 67.99 (unch)
ONCE : 110.05 (-3.10%)
ARQL : 20.00 (+0.15%)
Merger Monday, Biotech Edition: MRK, SNY, ARQL, THOR & More

Large-cap pharmaceutical companies are putting their assets to work in the biotech space, particularly in cancer treatment (oncology).

MRK : 76.55 (+3.73%)
RHHBY : 41.4700 (+1.64%)
SNY : 43.24 (+0.77%)
THOR : 67.99 (unch)
ONCE : 110.05 (-3.10%)
ARQL : 20.00 (+0.15%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +0.13 , SEDG -1.65 , THC +0.01 , TER +0.19 , LITE +0.40
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar